GSK (GSK) Announces 75.6% Vaccine Effectiveness for Arexvy in Real-World RSV Study

GSK (NYSE:GSK) is one of the best value stocks to buy now. On February 17, GSK released new real-world evidence showing that its RSV (respiratory syncytial virus) vaccine, Arexvy, is associated with significant reductions in hospitalizations and severe complications among adults aged 60 and older. The data, drawn from a large-scale US study of over 2.5 million people, showed a 75.6% VE (vaccine effectiveness) against RSV-related hospitalization.

Notably, the study also found that the vaccine was associated with a 63.1% reduction in major adverse cardiovascular events, such as heart attacks and strokes, during RSV-related hospital stays. The research also highlighted the vaccine’s impact on underlying respiratory conditions. Among patients with COPD (chronic obstructive pulmonary disease), Arexvy was associated with a 74.4% reduction in severe flare-ups; for those with asthma, the reduction was 61.6%.

A separate nationwide study in Denmark even observed a 100% VE in preventing RSV-related hospitalizations among a specific cohort of COPD patients aged 60 and older. While these observational findings do not prove direct causation, they suggest that vaccination may play a critical role in preventing the cascading health failures often triggered by an RSV infection.

GSK (NYSE:GSK), together with its subsidiaries, researches, develops, and manufactures vaccines, specialty medicines, and general medicines to prevent and treat disease in the UK, the US, and internationally.

While we acknowledge the potential of GSK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and 11 Best Mining Stocks to Buy According to Wall Street.

Disclosure: None.